Get started
Author

Gavin P. Birch

Observed names: Birch, Gavin Peter, Gavin Birch
ORCID: 0000-0002-8490-6138
Observed ORCID: 0000-0002-8490-6138
OpenAlex ID: A5073554716
Endo180 ( MRC2 ) Antibody–Drug Conjugate for the Treatment of Sarcoma
2022 · Rachel J. Evans, Douglas W. Perkins, et al. · Molecular Cancer Therapeutics · 18
Solid-phase synthesis of biocompatible N-heterocyclic carbene–Pd catalysts using a sub-monomer approach
2019 · Durgadas Cherukaraveedu, Paul T. Cowling, et al. · Organic & Biomolecular Chemistry · 13
PDF
Optical Molecular Imaging of Inflammatory Cells in Interventional Medicine–An Emerging Strategy
2019 · Gavin P. Birch, Thane Campbell, et al. · Frontiers in Oncology · 10
PDF
Abstract 479: SONNET 5010, a novel proprietary peptide drug conjugate lock and load platform.
2026 · John K. Cini, Susan Dexter, et al. · Cancer Research
Supplementary Table S1 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
PDF
Figure 2 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
Figure 3 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
Figure 5 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
Figure 4 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
Supplementary Figure S1 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
Figure 6 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
Supplementary Figure S2 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
Supplementary Figure S3 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
PDF
Supplementary Figure S5 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
PDF
Supplementary Figure S4 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
PDF
Supplementary Figure S7 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
PDF
Supplementary Figure S6 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2025 · Rachel J. Evans, Douglas W. Perkins, et al.
PDF
Supplementary Figure S2 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2023 · Rachel J. Evans, Douglas W. Perkins, et al.
Supplementary Figure S5 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2023 · Rachel J. Evans, Douglas W. Perkins, et al.
Supplementary Figure S1 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2023 · Rachel J. Evans, Douglas W. Perkins, et al.
PDF
Supplementary Figure S7 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2023 · Rachel J. Evans, Douglas W. Perkins, et al.
Supplementary Table S1 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2023 · Rachel J. Evans, Douglas W. Perkins, et al.
Supplementary Figure S6 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2023 · Rachel J. Evans, Douglas W. Perkins, et al.
PDF
Supplementary Figure S3 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2023 · Rachel J. Evans, Douglas W. Perkins, et al.
Supplementary Figure S5 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
2023 · Rachel J. Evans, Douglas W. Perkins, et al.
PDF
Works count: 32
Citation count: 41
H-index: 3
I10-index: 3
Year
Topic
Type